MDCX
Medicus PharmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MDCX
Medicus Pharma Ltd.
A biotechnology and life science company focused on accelerating clinical development plans for new and disruptive therapeutic assets
Biological Technology
04/30/2008
11/14/2024
NASDAQ Stock Exchange
12
12-31
Common stock
300 Conshohocken State Rd., Suite 200, W. Conshohocken, PA 19428
--
Medicus Pharma Ltd., was incorporated on April 30, 2008 under the laws of the province of Ontario, Canada. They are a biotechnology and life sciences company focused on accelerating clinical development programs for new and disruptive therapeutic assets. Currently, they are developing a product, SkinJectTM, for the treatment of basal cell carcinoma. Through its wholly-owned subsidiary SkinJect, Inc., they are focused on developing their licensed drug-device portfolio products for the treatment of non-lanoma skin cancer using novel dissolvable microneedle arrays. Their joint product candidate is doxorubicin tip-loaded D-MNA submitted to the U.S. Food and Drug Administration (" FDA ") under a new drug research application, regulated by the Center for Drug Evaluation and Registry in Oncology (CDER).
Company Financials
EPS
MDCX has released its 2025 Q2 earnings. EPS was reported at -0.43, versus the expected -0.26, missing expectations. The chart below visualizes how MDCX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
